Effect of body mass index on Argatroban therapy during percutaneous coronary intervention

Journal of Thrombosis and Thrombolysis

Volumn 25, Issue 3, 2008, Pages 273-279

  Hursting, Marcie J ^a   Jang, Ik Kyung ^b  

^a Clinical Science Consulting   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Argatroban; Body mass index; Obesity; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; HEPARIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; BODY MASS; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD COAGULATION; BODY MASS INDEX; CORONARY ARTERY DISEASE; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; MALE; MIDDLE AGED; OBESITY; PIPECOLIC ACIDS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 44649177574     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0051-7     Document Type: Article

References (23)

1. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F (2002) Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 57:177-184
2. Argatroban Package Insert (2005) Research Triangle Park. GlaxoSmithKline, NC
3. Lewis BE, Wallis DE, Berkowitz SD et al (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103:1838-1843
4. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163:1849-1856
5. Swan SK, Hursting MJ (2000) The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 20:318-329
6. Cox DS, Kleiman NS, Boyle DA et al (2004) Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein Ilb/IIIa receptor antagonist in patients undergoing percutaneous coronary intervention. J Clin Pharmacol 44:981-990
7. Murray PT, Reddy BV, Grossman EJ et al (2004) A prospective study of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66:2446-2453
8. Guzzi LM, McCollum DA, Hursting MJ (2006) Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 22:169-176
9. Jang IK, Lewis BE, Matthai WH, Kleiman NS (2004) Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J Thromb Thrombolysis 18:31-37
10. Rana JS, Mittleman MA, Ho KK, Cutlip DE (2005) Obesity and clinical restenosis after coronary stent placement. Am Heart J 150:821-826
11. Martin JL, Jia G, Martin SS et al (2006) The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice. Catheter Cardiovasc Interv 67:563-570
12. Rice L, Hursting MJ, Baillie GM, McCollum DA (2007) Argatroban anticoagulation in obese versus non-obese patients: Implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol, in press
13. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39:215-231
14. Blouin RA, Warren GW (1999) Pharmacokinetic considerations in obesity. J Pharm Sci 88:1-7
15. Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231
16. Rice L, Hursting MJ, McCollum DA (2006) Argatroban anticoagulation for heparin-induced thrombocytopenia in obese, versus nonobese, patients [abstract]. Blood 106(11 part 1):431a
17. Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J (2002) Monitoring of argatroban in ARG310 study: Potential recommendations for its use in interventional cardiology. Clin Appl Thromb Hemost 8:217-24
18. Shapiro NL, Durr EA, Krueger CD (2006) Prolonged anticoagulation after discontinuation of argatroban and warfarin therapy in an obese patient with heparin-induced thrombocytopenia. Pharmacotherapy 26:1806-1810
19. Erstad BL (2004) Dosing of medication in morbidly obese patients in the intensive care unit setting. Intensive Care Med 30:18-32
20. Baker MS, Skoyles RS, Shajar FM, Skinner H, Richens D, Mitchell IM (2005) Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass? J Extra Corpor Technol 37:153-156
21. Lui HK (2000) Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 12(Suppl F):41F-51F
22. Lincoff AM, Bittl JA, Harrington RA et al (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA 289:853-863
23. Ellis SG, Elliott J, Horrigan M, Raymond RE, Howell G (1996) Low-normal or excessive body mass index: Newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 78:642-646